Kyowa Kirin

Emerging Company in the Spotlight sponsored by JFK Communications.

BioNJ is pleased to shine the spotlight on one of our Innovation Members each month featuring their progress and work on behalf of Patients and their impact on the New Jersey life sciences ecosystem. This month’s Emerging Company in the Spotlight is Kyowa Kirin.

So many of our Members are making a dramatic impact on our State’s innovation ecosystem. We celebrate you! Kyowa Kirin is one such company.

Kyowa Kirin, Inc. (KKI) is the U.S. commercial entity of Kyowa Hakko Kirin Co., Ltd. (KHK), the Japan-based global specialty pharmaceutical company. Kyowa Kirin, Inc. is based in Bedminster, NJ and employs 65 people across the United States.
In 2011, KHK acquired Scotland-based international specialty pharma company, ProStrakan, in line with its strategy to develop a western life sciences footprint. ProStrakan rebranded as Kyowa Kirin International in 2016 as part of a move to create consistency across all of KHK’s international subsidiaries. That same year, the KHK annual report forecast that its U.S. business could be the biggest growth driver in the next five years.
KKI focuses on commercializing products to treat diseases for which there is an unmet medical need. In the United States, KKI currently offers two products in the oncology arena, Sancuso® (Granisetron Transdermal System) and Fareston® (toremifene citrate) 60 mg Tablets. Growth plans include seeking the approval of three internal pipeline products as well as potential in-licensing and other business development opportunities. KKI is very proud of its pipeline which may broaden its oncology portfolio and open new therapeutic areas in both the orphan and specialty spaces.
  • KW-6002 – Parkinson’s Disease: A first-in-class adenosine A2A receptor antagonist antiparkinsonian agent is currently in a global phase three clinical trial.
  • KW-0761 – Adult T-Cell Leukemia-Lymphoma (ATL) and Cutaneous T-Cell Lymphoma (CTCL): Received orphan-drug designation for treating patients with CTCL, it is designed to kill its target cells through potent antibody-dependent cellular cytoxicity and is currently in phase three clinical development. KW-0761 received the Best of ASCO award at the 2016 American Society of Clinical Oncology Annual Meeting.
  • KRN23 – X-Linked Hypophosphatemia (XLH): An investigational recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone Fibroblast Growth Factor 23 (FGF23). XLH is a bone disease characterized by phosphate-wasting which leads to a spectrum of skeletal abnormalities, physical impairment, weakness and pain.
As KHK anticipates growth in the U.S., KKI’s New Jersey office anticipates increased hiring. KKI is quickly becoming a larger company, but maintains a small company culture. As it continues to hire, KKI hopes to bring in new employees that share the qualities that make current KKI employees successful.
Len Paolillo, President of KKI, says: “Both our home office and field-based teams devote themselves to delivering medicines that improve the health and well being of patients. As the commercialization of our pipeline products and continued strategic in-licensing drive the expansion of our company, the patient, healthcare professionals and caregivers we serve will remain at the center of our activities. Employees at KKI are problem solvers, driven to action, resourceful and work urgently.”

Visit the company’s Careers Page at www.kyowa-kirin.com for information on career opportunities at Kyowa Kirin, Inc. For strategic partnerships, please contact the Business Development Team at Businessdevelopment-US@kyowakirin.com.